Prednimustine treatment in malignant lymphomas.

Abstract

Prednimustine (Stereocyt, Leo 1031) is a chlorambucil ester of prednisolone. Results from clinical trials confirm that prednimustine is active in malignant lymphomas. The efficacy of Stereocyt was evaluated in 25 patients, who were divided into three subgroups: 10 patients with refractory Hodgkin's disease and 7 with refractory non-Hodgkin lymphoma (NHL), while 8 patients received prednimustine as primary therapy for low-grade NHL. Totally 17 partial remissions were observed in all three groups of patients. Leukopenia and thrombopenia were induced in 3 patients, but were mild and reversible after withdrawal of the drug.

• Authors: I Szántó, T Fleischmann, S Eckhardt
• Journal: Oncology (Oncology) Vol. 46 Issue 4 Pg. 205-7 ( 1989) ISSN: 0030-2414 [Print] Switzerland
• PMID: 2662086 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Chlorambucil
• Prednimustine

Topics

• Adult
• Aged
• Chlorambucil (analogs & derivatives)
• Clinical Trials as Topic
• Female
• Hodgkin Disease (drug therapy)
• Humans
• Lymphoma, Non-Hodgkin (drug therapy)
• Male
• Middle Aged
• Prednimustine (therapeutic use)
• Remission Induction